Valuation: AIT Therapeutics Inc

Market Cap 4.02M 3.52M 3.25M 2.99M 5.64M 387M 5.76M 38.74M 15.24M 189M 15.1M 14.77M 653M P/E 2025
-0.4x
P/E 2026 -0.17x
Enterprise Value 15.76M 13.8M 12.75M 11.73M 22.1M 1.52B 22.6M 152M 59.75M 742M 59.2M 57.89M 2.56B EV / Sales 2025
7.78x
EV / Sales 2026 2.48x
Free-Float
90.09%
Yield 2025 *
-
Yield 2026 -
Manager TitleAgeSince
Chief Executive Officer 61 26/03/2026
Director of Finance/CFO 53 04/01/2026
Chief Tech/Sci/R&D Officer - 31/03/2024
Director TitleAgeSince
Director/Board Member 58 09/08/2017
Director/Board Member 54 01/01/2018
Director/Board Member 64 12/08/2018
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 4.02M
+1.87%+7.19%-18.59%-5.86% 175B
-0.43%-0.80%-7.15%-3.93% 106B
-0.03%+1.47%+5.13%+60.04% 59.91B
+0.66%+0.96%+37.64%+54.65% 51.95B
-1.10%+4.10%-11.56%-38.29% 43.58B
-3.21%-3.05% - - 33.65B
-1.71%+2.25%-8.63%-44.43% 29.58B
-1.16%+1.28%+69.87%-6.85% 25.31B
-1.49%+0.85%-3.43%-4.01% 21.23B
Average -0.66%+1.58%+7.91%+1.41% 60.79B
Weighted average by Cap. +0.09%+2.75%-1.60%+3.40%

Financials

2025 2026
Net sales 3.7M 3.24M 3M 2.76M 5.19M 357M 5.31M 35.7M 14.04M 174M 13.91M 13.61M 602M 7.68M 6.72M 6.21M 5.71M 10.77M 739M 11.01M 74M 29.11M 361M 28.84M 28.2M 1.25B
Net income -46.62M -40.8M -37.7M -34.68M -65.36M -4.49B -66.84M -449M -177M -2.19B -175M -171M -7.58B -33.25M -29.1M -26.88M -24.73M -46.61M -3.2B -47.67M -320M -126M -1.56B -125M -122M -5.4B
Net Debt 4.77M 4.18M 3.86M 3.55M 6.69M 459M 6.84M 45.98M 18.08M 225M 17.92M 17.52M 775M 11.74M 10.28M 9.49M 8.74M 16.46M 1.13B 16.84M 113M 44.51M 553M 44.1M 43.13M 1.91B
Logo AIT Therapeutics Inc
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. It has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The Company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.
Employees
-